GTx initiates Phase IIb trial of Capesaris for advanced prostate cancer

GTx, Inc. has announced the initiation of  a randomized Phase IIb trial of their selective estrogen receptor α agonist Capsesaris™ (previously known as GTx-758) versus leuprolide acetate (Lupron Depot®) as first-line androgen deprivation therapy for progressive and advanced forms of prostate cancer. … READ MORE …